Myriad Genetics June 13 sued Counsyl Inc. for infringement of its breast cancer screening patents in federal district court (University of Utah Research Found. v. Counsyl, Inc.filed).
The suit is in response to a preemptive complaint filed by Counsyl against Myriad that claimed Counsyl’s breast cancer test product didn’t infringe Myriad’s patents 7 LSLR 976, 10/4/13, 12 MRLR 634, 10/2/13.
In its lawsuit filed in the U.S. District Court for the District of Utah, Salt Lake City-based Myriad alleged that Counsyl had infringed claims of six of its U.S. patents (7,250,497, 6,951,721, 6,051,379, 6,033,857, 5,753,441 and 5,747,282) ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.